摘要
脑出血后重启抗血小板治疗可降低患者发生重大闭塞性血管事件的风险,但同时也可能会增高出血风险。临床医生通常面临着脑出血后是否及何时重启抗血小板治疗的挑战性决定。文章对脑出血后重启抗血小板治疗的获益与风险进行了综述,旨在为临床治疗策略提供参考。
Restarting antiplatelet therapy after intracerebral hemorrhage reduces the risk of major occlusive vascular events,but it may also increase the risk of bleeding.Clinicians often face the challenging decision of whether and when to restart antiplatelet therapy after intracerebral hemorrhage.This article reviews the benefits and risks of restarting antiplatelet therapy after intracerebral hemorrhage,aiming to provide reference for clinical treatment strategies.
作者
赵天全
江鹏
严智
王恩任
Zhao Tianquan;Jiang Peng;Yan Zhi;Wang Enren(Department of Neurosurgery,the First Affiliated Hospital of Chengdu Medical College,Chengdu 610500,China)
出处
《国际脑血管病杂志》
2020年第11期857-862,共6页
International Journal of Cerebrovascular Diseases
关键词
脑出血
卒中
抗血小板聚集药
Cerebral hemorrhage
Stroke
Platelet aggregation inhibitors
